Characterizing mild cognitive impairment in Parkinson's disease
John C Dalrymple-Alford1, Leslie Livingston, Michael R MacAskill
1Van der Veer Institute for Parkinson's and Brain Research, Christchurch, New Zealand. john.dalrymple-alford@canterbury.ac.nz
Summary
Identifying mild cognitive impairment in Parkinson's disease (PD-MCI) is crucial. This study suggests specific criteria using 2 scores at -1.5 SD in one domain or 1 score at -1.5 SD in two domains to accurately identify PD-MCI patients.
Area of Science:
- Neuroscience
- Neurology
- Cognitive Science
Background:
- Growing interest in identifying Parkinson's disease with mild cognitive impairment (PD-MCI).
- Current diagnostic criteria for PD-MCI are widely disparate, leading to inconsistent identification.
- Accurate identification of PD-MCI is essential for understanding disease progression and developing targeted interventions.
Purpose of the Study:
- To assess the influence of different neuropsychological criteria on the identification of PD-MCI.
- To compare the distribution of cognitive performance in PD-MCI groups relative to control and Parkinson's disease with dementia (PD-D) groups.
- To propose suitable criteria for minimizing the inclusion of cognitively well patients in PD-MCI diagnoses.
Main Methods:
- Evaluated 143 Parkinson's disease patients and 50 matched controls on 20 cognitive measures across four domains.
- Classified non-demented PD patients using 12 different neuropsychological criteria for mild cognitive impairment (MCI).
- Compared the impact of these criteria on the proportion of identified PD-MCI cases and cognitive performance distributions.
Main Results:
- Different criteria resulted in substantial variation in PD-MCI case identification, ranging from 14% to 89%.
- Criteria requiring 2 specific deficit scores or deficits across 2 domains better balanced the identification of impaired and unimpaired cognition.
- Suggested criteria of 2 scores at -1.5 SD within a single domain (30% PD-MCI) or 1 score at -1.5 SD in each of 2 domains (37% PD-MCI) showed promise.
Conclusions:
- The choice of diagnostic criteria significantly impacts the identification rates of PD-MCI.
- Criteria balancing deficit scores and domain involvement are recommended for accurate PD-MCI identification.
- Proposed criteria using standardized scores (-1.5 SD) offer a more reliable approach to minimize misclassification of cognitively healthy individuals.
Related Concept Videos
Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
Parkinson's Disease: Overview
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
Parkinson Disease l: Introduction
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...


